Regulatory approvals in major markets like Japan are critical for medical device companies like Neuronetics. The expanded approval for NeuroStar TMS therapy system is likely to increase its market penetration and sales in Japan, which could have a positive impact on the company's financial performance in the short term. Investors typically view regulatory milestones as positive indicators of a company's growth trajectory, which can lead to increased investor confidence and a potential rise in stock price.